Endothelin-1 and osteoblastic metastasis.
作者信息
Mundy Gregory R
机构信息
Department of Cellular Biology, University of Texas Health Science Center, San Antonio, TX 78229, USA.
出版信息
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10588-9. doi: 10.1073/pnas.2035063100. Epub 2003 Sep 8.
Abstract
摘要
相似文献
1
Endothelin-1 and osteoblastic metastasis.
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10588-9. doi: 10.1073/pnas.2035063100. Epub 2003 Sep 8.
2
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9. doi: 10.1073/pnas.1830978100. Epub 2003 Aug 26.
3
Mechanisms of osteoblastic metastases: role of endothelin-1.
Clin Orthop Relat Res. 2003 Oct(415 Suppl):S67-74. doi: 10.1097/01.blo.0000093047.96273.4e.
4
Modification of an osteoconductive anorganic bovine bone mineral matrix with growth factors.
J Periodontol. 1999 Aug;70(8):834-9. doi: 10.1902/jop.1999.70.8.834.
5
[Recent advances in the regulation of bone remodeling].
Nihon Rinsho. 2004 Feb;62 Suppl 2:37-46.
6
Differential regulation of platelet-derived growth factor stimulated migration and proliferation in osteoblastic cells.
J Cell Biochem. 2004 Nov 1;93(4):741-52. doi: 10.1002/jcb.20138.
7
Activation of extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) by FGF-2 and PDGF-BB in normal human osteoblastic and bone marrow stromal cells: differences in mobility and in-gel renaturation of ERK1 in human, rat, and mouse osteoblastic cells.
Biochem Biophys Res Commun. 1997 Sep 8;238(1):134-9. doi: 10.1006/bbrc.1997.7256.
8
Different profiles of Ca2+ responses to endothelin-1 and PDGF in liver myofibroblasts during the process of cell differentiation.
Br J Pharmacol. 2007 Jul;151(6):816-27. doi: 10.1038/sj.bjp.0707269. Epub 2007 May 29.
9
Chemotactic responses of osteoblastic MC3T3-E1 cells toward zinc chloride.
Biol Trace Elem Res. 2001 Oct;83(1):49-55. doi: 10.1385/BTER:83:1:49.
10
[Biological function of bone cells on the PTH-driven anabolic effect].
Clin Calcium. 2012 Mar;22(3):373-9.
引用本文的文献
1
Role of Endothelin-1 in a Syndrome of Myelofibrosis and Osteosclerosis.
J Clin Endocrinol Metab. 2015 Nov;100(11):3971-4. doi: 10.1210/jc.2015-2729. Epub 2015 Sep 10.
2
Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.
Int J Clin Exp Med. 2015 Mar 15;8(3):3465-73. eCollection 2015.
3
Osteoblast differentiation profiles define sex specific gene expression patterns in craniosynostosis.
Bone. 2015 Jul;76:169-76. doi: 10.1016/j.bone.2015.03.001. Epub 2015 Mar 7.
4
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
J Natl Cancer Inst. 2014 Apr;106(4):dju013. doi: 10.1093/jnci/dju013. Epub 2014 Feb 24.
5
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.
6
Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
Prostate. 2011 May;71(6):615-25. doi: 10.1002/pros.21277. Epub 2010 Oct 18.
7
New developments in the medical management of prostate cancer.
Mayo Clin Proc. 2010 Jan;85(1):77-86. doi: 10.4065/mcp.2009.0442.
8
Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.
Prostate. 2008 Jul 1;68(10):1116-25. doi: 10.1002/pros.20776.
9
The future in advanced prostate cancer: take your partners or is the last dance for me?
Rev Urol. 2004;6 Suppl 10(Suppl 10):S29-44.
10
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Curr Oncol Rep. 2006 Mar;8(2):108-13. doi: 10.1007/s11912-006-0045-1.
本文引用的文献
1
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.
Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9. doi: 10.1073/pnas.1830978100. Epub 2003 Aug 26.
2
Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo.
J Clin Invest. 2002 Nov;110(10):1559-72. doi: 10.1172/JCI11936.
3
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458.
4
5
Markers of bone turnover in prostate cancer.
Cancer Treat Rev. 2001 Jun;27(3):187-92; discussion 193-6. doi: 10.1053/ctrv.2000.0213.
6
Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
Br J Cancer. 2000 Feb;82(4):858-64. doi: 10.1054/bjoc.1999.1012.
7
Peptide growth factors and prostate cancer: new models, new opportunities.
Cancer Metastasis Rev. 1998;17(4):317-24. doi: 10.1023/a:1006162410436.
8
[Diagnostic value of urinary N-telopeptide of type I collagen in prostate cancer: comparison with bone scintigraphy].
Kaku Igaku. 1999 May;36(4):333-9.
9
Effect of bone proteins on human prostate cancer cell lines in vitro.
Prostate. 1998 Jun 15;36(1):14-22. doi: 10.1002/(sici)1097-0045(19980615)36:1<14::aid-pros3>3.0.co;2-b.
10
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
J Clin Invest. 1996 Oct 1;98(7):1544-9. doi: 10.1172/JCI118947.
Zotero 插件